Regeneron to Acquire 23andMe’s Key Assets for $256 Million, Expanding Genetic Data Capabilities

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has emerged as the successful bidder in the bankruptcy auction for the majority of assets owned by 23andMe Holding Co., a leading name in human genetics and biotechnology. The $256 million acquisition includes 23andMe’s Personal Genome Service® (PGS), Total Health and Research Services business lines, as well as its extensive Biobank. The transaction is expected to close in the third quarter of 2025, pending regulatory approvals and other customary conditions.

As part of this acquisition, Regeneron plans to maintain 23andMe’s consumer genome services without interruption. The company has also assured compliance with 23andMe’s existing consumer privacy policies and applicable laws, with a court-appointed, independent Customer Privacy Ombudsman overseeing data privacy and security measures.

“Regeneron was among the first biotech companies to recognize the transformative power of DNA, driving our innovation in drug discovery and development,” stated George D. Yancopoulos, M.D., Ph.D., co-Founder, Board co-Chair, President, and Chief Scientific Officer of Regeneron. “We are excited to help 23andMe continue its mission of empowering individuals with insights into their genetic information, while advancing our own efforts in genetics-driven medical research.”

Following the acquisition, 23andMe will operate as a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. It will continue offering personal genomics services, while Regeneron integrates 23andMe’s genetic data to further its research capabilities. The deal does not include 23andMe’s Lemonaid Health business.

Aris Baras, MD, Senior Vice President and Head of the Regeneron Genetics Center, emphasized the importance of data security and privacy, stating, “We are committed to protecting the 23andMe dataset with the highest standards of data privacy, security, and ethical oversight. Our experience in large-scale genetics will enhance 23andMe’s platform while benefiting medical research globally.”

Joe Selsavage, Interim Chief Executive Officer of 23andMe, expressed optimism about the agreement, highlighting Regeneron’s expertise in genetic sequencing and its commitment to continuing 23andMe’s mission. "With Regeneron’s support, we look forward to furthering our mission of helping people access and understand the human genome for improved health outcomes," Selsavage noted.